Figure 1.
Overall survival and PFS. (A) Overall survival and PFS in all patients (B) PFS based on pretransplantation–brentuximab vedotin exposure; PFS includes 95% CI.

Overall survival and PFS. (A) Overall survival and PFS in all patients (B) PFS based on pretransplantation–brentuximab vedotin exposure; PFS includes 95% CI.

Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal